Difference between revisions of "Disturbance in neuroendocrine regulation"

From Aging Chart
Jump to: navigation, search
(Autoloading by CXLParser)
(Autoloading by CXLParser)
 
Line 359: Line 359:
 
(.//.)<html><!--Pop-up for: Hypothermy !Pop-up-->
 
(.//.)<html><!--Pop-up for: Hypothermy !Pop-up-->
 
<div class="1HX3RQPJM-DYNF1Q-9F" style="display:none;">
 
<div class="1HX3RQPJM-DYNF1Q-9F" style="display:none;">
 +
  
  
Line 370: Line 371:
 
</div>(...)<!--Pop-up for: Acetylcholine !Pop-up-->
 
</div>(...)<!--Pop-up for: Acetylcholine !Pop-up-->
 
<div class="1ND6LVXLL-1PM825R-ZJZ" style="display:none;">
 
<div class="1ND6LVXLL-1PM825R-ZJZ" style="display:none;">
 +
  
  
Line 381: Line 383:
 
</div>(...)<!--Pop-up for: Serotonin !Pop-up-->
 
</div>(...)<!--Pop-up for: Serotonin !Pop-up-->
 
<div class="1ND6LWK53-1Z9SD8W-ZK9" style="display:none;">
 
<div class="1ND6LWK53-1Z9SD8W-ZK9" style="display:none;">
 +
  
  
Line 392: Line 395:
 
</div>(...)<!--Pop-up for: Neuroendocrine system !Pop-up-->
 
</div>(...)<!--Pop-up for: Neuroendocrine system !Pop-up-->
 
<div class="1P0DRK0FJ-1MTL677-2FN" style="display:none;">
 
<div class="1P0DRK0FJ-1MTL677-2FN" style="display:none;">
 +
  
 
<h3>Neuroendocrine system</h3>
 
<h3>Neuroendocrine system</h3>
Line 397: Line 401:
 
</div>(...)<!--Pop-up for: Hypometabolism !Pop-up-->
 
</div>(...)<!--Pop-up for: Hypometabolism !Pop-up-->
 
<div class="1HWXX7KSJ-1M383F8-1LZ" style="display:none;">
 
<div class="1HWXX7KSJ-1M383F8-1LZ" style="display:none;">
 +
  
  
Line 408: Line 413:
 
</div>(...)<!--Pop-up for: Hypometabolism !Pop-up-->
 
</div>(...)<!--Pop-up for: Hypometabolism !Pop-up-->
 
<div class="1HX10QYNR-1G7KK32-M0" style="display:none;">
 
<div class="1HX10QYNR-1G7KK32-M0" style="display:none;">
 +
  
  
Line 419: Line 425:
 
</div>(...)<!--Pop-up for: DHEA !Pop-up-->
 
</div>(...)<!--Pop-up for: DHEA !Pop-up-->
 
<div class="1ND6L3N79-1XS6DW-Z31" style="display:none;">
 
<div class="1ND6L3N79-1XS6DW-Z31" style="display:none;">
 +
  
  
Line 430: Line 437:
 
</div>(...)<!--Pop-up for: Dehydration  Of tissues !Pop-up-->
 
</div>(...)<!--Pop-up for: Dehydration  Of tissues !Pop-up-->
 
<div class="1HX117ND0-LB9J37-YG" style="display:none;">
 
<div class="1HX117ND0-LB9J37-YG" style="display:none;">
 +
  
  
Line 441: Line 449:
 
</div>(...)<!--Pop-up for: IGF-1 !Pop-up-->
 
</div>(...)<!--Pop-up for: IGF-1 !Pop-up-->
 
<div class="1HWXVJC2Z-2917DY-FJ" style="display:none;">
 
<div class="1HWXVJC2Z-2917DY-FJ" style="display:none;">
 +
  
  
Line 452: Line 461:
 
</div>(...)<!--Pop-up for: Homoplasy of defective mtDNA !Pop-up-->
 
</div>(...)<!--Pop-up for: Homoplasy of defective mtDNA !Pop-up-->
 
<div class="1HXDHKF61-S97LC9-B0" style="display:none;">
 
<div class="1HXDHKF61-S97LC9-B0" style="display:none;">
 +
  
  
Line 463: Line 473:
 
</div>(...)<!--Pop-up for: Trophic function  Of neurons and glia !Pop-up-->
 
</div>(...)<!--Pop-up for: Trophic function  Of neurons and glia !Pop-up-->
 
<div class="1HWXX43QN-XL1KJM-1HJ" style="display:none;">
 
<div class="1HWXX43QN-XL1KJM-1HJ" style="display:none;">
 +
  
  
Line 474: Line 485:
 
</div>(...)<!--Pop-up for: Sleep Disorders !Pop-up-->
 
</div>(...)<!--Pop-up for: Sleep Disorders !Pop-up-->
 
<div class="1HWXY5Q78-1VF1JLP-2BK" style="display:none;">
 
<div class="1HWXY5Q78-1VF1JLP-2BK" style="display:none;">
 +
  
  
Line 485: Line 497:
 
</div>(...)<!--Pop-up for: Neurodegeneration !Pop-up-->
 
</div>(...)<!--Pop-up for: Neurodegeneration !Pop-up-->
 
<div class="1HWXX3RKV-17W6RYJ-1GF" style="display:none;">
 
<div class="1HWXX3RKV-17W6RYJ-1GF" style="display:none;">
 +
  
  
Line 496: Line 509:
 
</div>(...)<!--Pop-up for: Neurotransmitter receptors  !Pop-up-->
 
</div>(...)<!--Pop-up for: Neurotransmitter receptors  !Pop-up-->
 
<div class="1ND6LX3LL-1FNWX9D-ZKK" style="display:none;">
 
<div class="1ND6LX3LL-1FNWX9D-ZKK" style="display:none;">
 +
  
  
Line 507: Line 521:
 
</div>(...)<!--Pop-up for: Osteoporosis !Pop-up-->
 
</div>(...)<!--Pop-up for: Osteoporosis !Pop-up-->
 
<div class="1HWXY68FF-2BQZ1FQ-2CK" style="display:none;">
 
<div class="1HWXY68FF-2BQZ1FQ-2CK" style="display:none;">
 +
  
  
Line 518: Line 533:
 
</div>(...)<!--Pop-up for: Regenerative processes !Pop-up-->
 
</div>(...)<!--Pop-up for: Regenerative processes !Pop-up-->
 
<div class="1HX10RDVH-976BN4-NN" style="display:none;">
 
<div class="1HX10RDVH-976BN4-NN" style="display:none;">
 +
  
  
Line 529: Line 545:
 
</div>(...)<!--Pop-up for: Dopamine !Pop-up-->
 
</div>(...)<!--Pop-up for: Dopamine !Pop-up-->
 
<div class="1ND6LVN24-2BY27VR-ZJS" style="display:none;">
 
<div class="1ND6LVN24-2BY27VR-ZJS" style="display:none;">
 +
  
  
Line 540: Line 557:
 
</div>(...)<!--Pop-up for: Depression !Pop-up-->
 
</div>(...)<!--Pop-up for: Depression !Pop-up-->
 
<div class="1HWXX9VWS-TL3YX-1PQ" style="display:none;">
 
<div class="1HWXX9VWS-TL3YX-1PQ" style="display:none;">
 +
  
  
Line 551: Line 569:
 
</div>(...)<!--Pop-up for: Impaired hypothalamic feedback affecting on production of statins and liberins !Pop-up-->
 
</div>(...)<!--Pop-up for: Impaired hypothalamic feedback affecting on production of statins and liberins !Pop-up-->
 
<div class="1HX10NDVN-4Y453T-HB" style="display:none;">
 
<div class="1HX10NDVN-4Y453T-HB" style="display:none;">
 +
  
  
Line 562: Line 581:
 
</div>(...)<!--Pop-up for: Testosterone !Pop-up-->
 
</div>(...)<!--Pop-up for: Testosterone !Pop-up-->
 
<div class="1ND6L3W7Q-VBXSC8-Z35" style="display:none;">
 
<div class="1ND6L3W7Q-VBXSC8-Z35" style="display:none;">
 +
  
  
Line 573: Line 593:
 
</div>(...)<!--Pop-up for: Metabolic syndrome !Pop-up-->
 
</div>(...)<!--Pop-up for: Metabolic syndrome !Pop-up-->
 
<div class="1HWXY7NLJ-HDKMPZ-2DF" style="display:none;">
 
<div class="1HWXY7NLJ-HDKMPZ-2DF" style="display:none;">
 +
  
  
Line 584: Line 605:
 
</div>(...)<!--Pop-up for: Involution of pineal gland !Pop-up-->
 
</div>(...)<!--Pop-up for: Involution of pineal gland !Pop-up-->
 
<div class="1HWXVFHPD-1YL35XV-7Z" style="display:none;">
 
<div class="1HWXVFHPD-1YL35XV-7Z" style="display:none;">
 +
  
  
Line 595: Line 617:
 
</div>(...)<!--Pop-up for: Neurotransmitters !Pop-up-->
 
</div>(...)<!--Pop-up for: Neurotransmitters !Pop-up-->
 
<div class="1HWXW5SH4-253B0GL-VL" style="display:none;">
 
<div class="1HWXW5SH4-253B0GL-VL" style="display:none;">
 +
  
  
Line 606: Line 629:
 
</div>(...)<!--Pop-up for: Sex steroids !Pop-up-->
 
</div>(...)<!--Pop-up for: Sex steroids !Pop-up-->
 
<div class="1HWXVZ5T7-29RQFC8-PW" style="display:none;">
 
<div class="1HWXVZ5T7-29RQFC8-PW" style="display:none;">
 +
  
  
Line 617: Line 641:
 
</div>(...)<!--Pop-up for: Norepinephrine !Pop-up-->
 
</div>(...)<!--Pop-up for: Norepinephrine !Pop-up-->
 
<div class="1ND6LW6N4-CJ98L7-ZK5" style="display:none;">
 
<div class="1ND6LW6N4-CJ98L7-ZK5" style="display:none;">
 +
  
  
Line 628: Line 653:
 
</div>(...)<!--Pop-up for: Growth hormone !Pop-up-->
 
</div>(...)<!--Pop-up for: Growth hormone !Pop-up-->
 
<div class="1HWXVHJGD-1DYMSKY-CY" style="display:none;">
 
<div class="1HWXVHJGD-1DYMSKY-CY" style="display:none;">
 +
  
  
Line 639: Line 665:
 
</div>(...)<!--Pop-up for: Estradiol !Pop-up-->
 
</div>(...)<!--Pop-up for: Estradiol !Pop-up-->
 
<div class="1ND6L45XV-12QT66Z-Z39" style="display:none;">
 
<div class="1ND6L45XV-12QT66Z-Z39" style="display:none;">
 +
  
  
Line 650: Line 677:
 
</div>(...)<!--Pop-up for: Cerebrovascular deterioration !Pop-up-->
 
</div>(...)<!--Pop-up for: Cerebrovascular deterioration !Pop-up-->
 
<div class="1HX3RS7MP-28R9433-G7" style="display:none;">
 
<div class="1HX3RS7MP-28R9433-G7" style="display:none;">
 +
  
  
Line 661: Line 689:
 
</div>(...)<!--Pop-up for: Reproduction !Pop-up-->
 
</div>(...)<!--Pop-up for: Reproduction !Pop-up-->
 
<div class="1HX10WDC8-11S5858-RL" style="display:none;">
 
<div class="1HX10WDC8-11S5858-RL" style="display:none;">
 +
  
  
Line 672: Line 701:
 
</div>(...)<!--Pop-up for: GABA !Pop-up-->
 
</div>(...)<!--Pop-up for: GABA !Pop-up-->
 
<div class="1ND6LWT56-23RSN3C-ZKF" style="display:none;">
 
<div class="1ND6LWT56-23RSN3C-ZKF" style="display:none;">
 +
  
  
Line 683: Line 713:
 
</div>(...)<!--Pop-up for: Vasopressin !Pop-up-->
 
</div>(...)<!--Pop-up for: Vasopressin !Pop-up-->
 
<div class="1HWXW94LH-1NY84VS-YW" style="display:none;">
 
<div class="1HWXW94LH-1NY84VS-YW" style="display:none;">
 +
  
  
Line 694: Line 725:
 
</div>(...)<!--Pop-up for: Thyroid hormone T4 !Pop-up-->
 
</div>(...)<!--Pop-up for: Thyroid hormone T4 !Pop-up-->
 
<div class="1HWXVMDC9-NBF294-MR" style="display:none;">
 
<div class="1HWXVMDC9-NBF294-MR" style="display:none;">
 +
  
  
Line 705: Line 737:
 
</div>(...)<!--Pop-up for: Distress  !Pop-up-->
 
</div>(...)<!--Pop-up for: Distress  !Pop-up-->
 
<div class="1HWXWHXQB-9XLST-177" style="display:none;">
 
<div class="1HWXWHXQB-9XLST-177" style="display:none;">
 +
  
  
Line 716: Line 749:
 
</div>(...)<!--Pop-up for: Melatonin !Pop-up-->
 
</div>(...)<!--Pop-up for: Melatonin !Pop-up-->
 
<div class="1HWXVG5P5-FS2WZ0-9C" style="display:none;">
 
<div class="1HWXVG5P5-FS2WZ0-9C" style="display:none;">
 +
  
  
Line 727: Line 761:
 
</div>(...)<!--Pop-up for: Impaired functions of pituitary gland, peripheral endocrine glands, diffuse endocrine system !Pop-up-->
 
</div>(...)<!--Pop-up for: Impaired functions of pituitary gland, peripheral endocrine glands, diffuse endocrine system !Pop-up-->
 
<div class="1HWXVJY9W-10DN886-GV" style="display:none;">
 
<div class="1HWXVJY9W-10DN886-GV" style="display:none;">
 +
  
  
Line 738: Line 773:
 
</div>(...)<!--Pop-up for: Hyperproduction of  Glucocorticoids !Pop-up-->
 
</div>(...)<!--Pop-up for: Hyperproduction of  Glucocorticoids !Pop-up-->
 
<div class="1HWXW9TYY-S4JKXY-10F" style="display:none;">
 
<div class="1HWXW9TYY-S4JKXY-10F" style="display:none;">
 +
  
  
Line 749: Line 785:
 
</div>(...)<!--Pop-up for: Progesterone !Pop-up-->
 
</div>(...)<!--Pop-up for: Progesterone !Pop-up-->
 
<div class="1ND6L4G0C-GP6N5S-Z3F" style="display:none;">
 
<div class="1ND6L4G0C-GP6N5S-Z3F" style="display:none;">
 +
  
  

Latest revision as of 09:26, 2 August 2015

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Disturbance in neuroendocrine regulation

The neuroendocrine system (NES) of Vertebrates can be defined as a set of cells organized in single organs and diffuse elements, sharing co-production of amine hormone/transmitters, peptide hormone/transmitters and specific markers of neural determination. In this perspective, the hypothalamic-pituitary-target organ axis (H-P axis), the autonomic nervous system (ANS) and the diffuse neuroendocrine or APUD system contribute to the NES.

The consequences of ageing of the neuroendocrine system have been incriminated in the development of various age-dependent conditions, such as insulin resistance, osteoporosis, muscular atrophy and abnormalities of fat deposition. Ageing affects the endocrine system by altering endocrine cells, the hormones produced by these cells and hormone receptors or postreceptor processes in the target cells.

Dopaminergic innervation of the hypothalamus comprises at least three neuronal systems. These are the tuberinfundibular dopamine system, the tuberohypophyseal dopamine system, and the incertohypothalamic dopamine system. The tuberinfundibular dopamine system shows the most dramatic age-related changes. Marked decreases in dopamine concentrations with age have been observed in the medial basal hypothalamus, containing primarily tuberinfundibular dopamine neurons. In contrast to the tuberinfundibular system, the tuberohypophyseal and ncertohypothalamic dopamine systems show varying responses to aging. Dopamine receptors can be divided into two major subtypes: D-1 and D-2. Age-related decreases in D-2 receptor subtypes occur in the caudate nucleus, putamen, substantia nigra and globus pallidus. In contrast, D-1 receptors have been reported to increase or show no change with age. There is a steady decline in dopaminergic cells in the substantia nigra with age in humans. The number of dopaminergic neurones in each substantia nigra declines from 400 000 at birth to 250 000 at age 60.

The serotonin (5-HT) responses to increasing age are variable. Total brain 5-HT levels decrease with age, but hindbrain 5-HT levels do not change. Depression is associated with a depletion of noradrenaline and serotonin. Age-related increase in MAO (monoamine oxidase) in the brain, which breaks down 5-HT and noradrenaline to 5-hydroxyindoleacetic acid and 4-hydroxy 3-methoxy D-mandelic acid, may predispose elderly people to depression. Serotonin is one of the main regulators of circadian sleep/wake cycles, and deficiency of serotonin is associated with many psychiatric and neurological disorders, including sleep disorders and some forms of dementia.

Episodic GH secretion becomes markedly impaired with ageing. This is due to a reduction in pulse amplitude, although pulse frequency remains unchanged. Sleep-related secretion of GH appears to be primarily dependent on the release of GH-releasing hormone. Age-related decrements in sleep-related GH secretion may play a role in the hyposomatotropism of senescence. Catecholaminergic alterations in the hypothalamus may be responsible for the reduced GH secretion in old age, as suggested by the restoration of GH pulse amplitudes in old male rats by repetitive injections of catecholamine precursors. Since acetylcholine inhibits hypothalamic somatostatin release, the reduced cholinergic tone in elderly subjects may result in an increased somatostatinergic tone.